Literature DB >> 18025841

Desipramine induces apoptotic cell death through nonmitochondrial and mitochondrial pathways in different types of human colon carcinoma cells.

Hideki Arimochi1, Kyoji Morita.   

Abstract

Cytotoxic effects of desipramine on human colon carcinoma HT29 and HCT116 cells were examined. Desipramine reduced the viability of HT29 cells in a concentration-dependent manner, but failed to cause any significant change in the viability of HCT116 cells by the concentration up to 50 mumol/l, at which an approximately 60% reduction of the viability of HT29 cells was observed. Despite their different sensitivities, desipramine caused the nonoxidative apoptotic damage to both of them. In contrast to HT29 cells, desipramine might cause the apoptotic death of HCT116 cells through the disturbance of mitochondrial function. These results suggest that desipramine may cause the nonoxidative apoptotic damage to different types of human colon carcinoma cells through either a nonmitochondrial or a mitochondrial pathway, which may confer the different sensitivities to this drug on these tumor cells. (c) 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18025841     DOI: 10.1159/000111144

Source DB:  PubMed          Journal:  Pharmacology        ISSN: 0031-7012            Impact factor:   2.547


  14 in total

1.  Platinum anticancer agents and antidepressants: desipramine enhances platinum-based cytotoxicity in human colon cancer cells.

Authors:  Peyman Kabolizadeh; Brigitte J Engelmann; Nicholas Pullen; Jennifer K Stewart; John J Ryan; Nicholas P Farrell
Journal:  J Biol Inorg Chem       Date:  2011-09-15       Impact factor: 3.358

Review 2.  Novel Sphingolipid-Based Cancer Therapeutics in the Personalized Medicine Era.

Authors:  Jeremy Shaw; Pedro Costa-Pinheiro; Logan Patterson; Kelly Drews; Sarah Spiegel; Mark Kester
Journal:  Adv Cancer Res       Date:  2018-06-19       Impact factor: 6.242

3.  Relationship between anti-depressant use and lung cancer survival.

Authors:  Adriana Zingone; Derek Brown; Elise D Bowman; Oscar Vidal; Julien Sage; Joel Neal; Bríd M Ryan
Journal:  Cancer Treat Res Commun       Date:  2017-01-29

4.  Desipramine induces apoptosis in rat glioma cells via endoplasmic reticulum stress-dependent CHOP pathway.

Authors:  Jian Ma; Yu Qiu; Lan Yang; Liang Peng; Zheng Xia; Li-Na Hou; Chao Fang; Hong Qi; Hong-Zhuan Chen
Journal:  J Neurooncol       Date:  2010-06-12       Impact factor: 4.130

5.  Colorectal cancer risk in relation to antidepressant medication use.

Authors:  Jessica Chubak; Denise M Boudreau; Stephen J Rulyak; Margaret T Mandelson
Journal:  Int J Cancer       Date:  2011-01-01       Impact factor: 7.396

6.  Antidepressant Use and Risk of Colorectal Cancer in the Women's Health Initiative.

Authors:  Jenna F Kiridly-Calderbank; Susan R Sturgeon; Candyce H Kroenke; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-05-22       Impact factor: 4.254

7.  Arsenic trioxide inhibits HCCLM3 cells invasion through de novo ceramide synthesis and sphingomyelinase-induced ceramide production.

Authors:  ShiHai Zhang; Jing Zhou; CuiLing Zhang; HuiWen Wu; Yi Wang; JianMin Bian; Jun Guo; XiangYang Wu
Journal:  Med Oncol       Date:  2011-07-20       Impact factor: 3.064

Review 8.  Targeting Ion Channels for Cancer Treatment: Current Progress and Future Challenges.

Authors:  Alina L Capatina; Dimitris Lagos; William J Brackenbury
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

Review 9.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

10.  Antidepressant use and colorectal cancer risk.

Authors:  Patricia F Coogan; Brian L Strom; Lynn Rosenberg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-11       Impact factor: 2.890

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.